ArticlePloS one2026
Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze morphological and functional response after administration of a single dose of ranibizumab in eyes under treat&extend aflibercept in neovascular age related macular degeneration (nAMD). Additionally, we aimed to identify predictive factors in anti-vascular endothelial growth factor (VEGF) treatment.
methodsA total of 115 patients (133 eyes; 34 male, 81 female, m:f = 1:2.4) with a mean age of 79.9 ± 8.3 years at baseline (BSL) were included in this retrospective analysis. All eyes had received aflibercept treatment for nAMD before BSL and were subsequently administered a single dose of intravitreal ranibizumab. Data of two visits pre and two visits after BSL were evaluated and compared. Primary outcome measure was the mean change in central macular thickness (CMT, µm). CMT-changes between BSL and the next follow-up visit (V4) were roughly divided into decrease (<-10µm), equal (-10 to +10 µm) or increase (> +10µm). We also assessed changes in best-corrected visual acuity (BCVA) and identified influencing factors on CMT and BCVA using linear mixed models (LMM).
resultsNo significant differences in CMT and BCVA were observed over the visits (p > 0.05). Factors influencing CMT included prior anti-VEGF injections (p < 0.001), the time interval between BSL and visit 4 (p < 0.001), and patient age (p = 0.032). The number of prior anti-VEGF injections significantly influenced BCVA (p = 0.003). After a single administration of ranibizumab, in 19.5% (n = 26) of eyes CMT decreased, in 21.8% of eyes (n = 29) CMT increased and in 36.8% of eyes (n = 49) it remained equal.
conclusionOur study indicates that changes in CMT are affected by age, the number of previous injections, and the time interval between visits. These biomarkers may offer valuable insights for future research on switching anti-VEGF drugs to optimize treatment strategies for nAMD. A single dose treatment switch to ranibizumab yielded non-inferior outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.